Compare AXGN & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXGN | HCM |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1796 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | 2013 | N/A |
| Metric | AXGN | HCM |
|---|---|---|
| Price | $42.83 | $10.82 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 9 | 1 |
| Target Price | ★ $42.33 | $13.75 |
| AVG Volume (30 Days) | ★ 687.9K | 49.3K |
| Earning Date | 04-28-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $225,208,000.00 | N/A |
| Revenue This Year | $20.57 | $20.60 |
| Revenue Next Year | $16.68 | $15.62 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | ★ 20.21 | N/A |
| 52 Week Low | $9.22 | $11.00 |
| 52 Week High | $45.83 | $19.50 |
| Indicator | AXGN | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 60.10 | 21.10 |
| Support Level | $29.48 | N/A |
| Resistance Level | $44.83 | $15.59 |
| Average True Range (ATR) | 1.84 | 0.37 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 74.86 | 5.93 |
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.